Patents by Inventor Christopher Vakoc

Christopher Vakoc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
    Publication number: 20220071981
    Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 10, 2022
    Inventors: Gerd Blobel, Jeremy Grevet, Junwei Shi, Christopher Vakoc
  • Compositions and methods for hemoglobin production
    Patent number: 11179379
    Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: November 23, 2021
    Assignees: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, COLD SPRING HARBOR LABORATORY
    Inventors: Gerd Blobel, Jeremy Grevet, Junwei Shi, Christopher Vakoc
  • COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
    Publication number: 20190365734
    Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 5, 2019
    Inventors: Gerd Blobel, Jeremy Grevet, Junwei Shi, Christopher Vakoc
  • IDENTIFICATION OF RNAI TARGETS AND USE OF RNAI FOR RATIONAL THERAPY OF CHEMOTHERAPY-RESISTANT LEUKEMIA AND OTHER CANCERS
    Publication number: 20150283101
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Application
    Filed: November 3, 2014
    Publication date: October 8, 2015
    Inventors: Bruce STILLMAN, Scott W. LOWE, Anthony MAZUREK, Johannes Ekkehart ZUBER, Christopher VAKOC, Katherine MCJUNKIN
  • Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
    Patent number: 8895526
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: November 25, 2014
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Bruce Stillman, Scott W. Lowe, Anthony Mazurek, Johannes Ekkehart Zuber, Christopher Vakoc, Katherine McJunkin
  • IDENTIFICATION OF RNAI TARGETS AND USE OF RNAI FOR RATIONAL THERAPY OF CHEMOTHERAPY-RESISTANT LEUKEMIA AND OTHER CANCERS
    Publication number: 20120272346
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Application
    Filed: March 29, 2010
    Publication date: October 25, 2012
    Inventors: Bruce Stillman, Scott W. Lowe, Anthony Mazurek, Johannes Ekkehart Zuber, Christopher Vakoc, Katherine McJunkin